Guo-Kai Feng focuses on tumor targeted molecular imaging and therapy with integrin α6, KRas and EBV proteins as the main research targets. He's committed to develop tumor targeted molecular probes for the accurate detection of tumor, and tumor therapeutic drugs including peptide-conjugated drugs, antibody-conjugated drugs and PROTAC drugs for tumor targeted therapy. 
He has accumulated some experience in the transformation of scientific and technological achievements. An integrin α6 targeted PET probe developed by him has been shown to accurately detect of several kinds of tumors in an investigator-initiated trial. The intellectual property transformation of this probe has been achieved through equity investment by Sun Yat-sen University in 2022. Several developed integrin α6 targeted peptide-conjugated drugs and a pan-KRAS degrader have been proved to inhibit tumor growth in mice models. Meanwhile, as one of the contributors, he helps Professor Musheng  Zeng's team to complete the transformation of two scientific and technological achievements with a total contract amount of more than 500 million yuan in 2023. 
His research has been supported by one National Key Research and Development Programs, two general projects of National Natural Science Foundation of China, one Youth Fund project of National Natural Science Foundation of China, one Science and Technology Plan Fund of Guangdong Province, one Basic Research Fund for Central Universities, and one doctoral fund. 
He has published more than 20 papers as a corresponding or co-corresponding author in leading international journals, including Signal Transduction and Targeted Therapy, ACS nano, Advanced Science, Cell Discovery, Engineering, Journal of Controlled Release and European Journal of Nuclear Medicine and Molecular Imaging. 

Tumor targeted molecular imaging and therapy.

1. Promising Therapeutic Efficacy and Safety of a Novel Integrin α6-Targeting Peptide-Drug Conjugate in Lung Adenocarcinoma. Wuyou Gao^#, Qiaoli Wang^#, Shibing Li^#, Wanqi Chen^#, Bin Luo, Kaili Xie, Huaze Liao, Leqi Zhong, Youfang Chen*, Zhesheng Wen*, Guokai Feng*. Mol Cancer. 2025 Jul 5;24(1):190. doi: 10.1186/s12943-025-02395-7.

2. A pan-KRAS degrader for the treatment of KRAS-mutant cancers. Jie Yang^#, Qiao-Li Wang^#, Guan-Nan Wang, Jia-Cong Ye, Zi-Qian Li, Jing-Yun Wang, Zhao-Hui Liang, Shu-Xin Li, Cong Sun, Wen-Ting Liao, Yi-Jun Gao, Jing Wang, Guo-Kai Feng, Yong Mao, Chunjing Yu, Guo-Kai Feng* and Mu-Sheng Zeng*. Cell Discov. 2024 Jun 28;10(1):70. doi: 10.1038/s41421-024-00699-4.

3. Targeted therapy of central nervous system acute lymphoblastic leukemia with an integrin α6-targeted self-assembling proapoptotic nanopeptide. Jia-Cong Ye^#, Wan-Qiong Li^#, Mei-Ling Chen^#, Qian-Kun Shi^#, Hua Wang, Xin-Ling Li, Ying-He Li, Jie Yang, Qiao-Li Wang, Fang Hu, Yan-Feng Gao*, Shu-Wen Liu*, Mu-Sheng Zeng*, Guo-Kai Feng*. Engineering 2024.Volume 35, April 2024, Pages 226-240. doi: 10.1016/j.eng.2023.11.012.

4. EDB‑FN targeted probes for the surgical navigation, radionuclide imaging, and therapy of thyroid cancer. Ruping Li^#, Huihui He^#, Xinling Li^#, Xiaobin Zheng^#, Zhijian Li, Hu Zhang, Jiacong Ye, Weiguang Zhang, Chunjing Yu*, Guokai Feng*, Wei Fan*. Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):2100-2113. doi: 10.1007/s00259-023-06147-x. Epub 2023 Feb 18.

5. Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. Cong Sun, Yin-Feng Kang, Yuan-Tao Liu, Xiang-Wei Kong, Hui-Qin Xu, Dan Xiong, Chu Xie, Yi-Hao Liu, Sui Peng, Guo-Kai Feng*, Zheng Liu* and Mu-Sheng Zeng*. Signal Transduct Target Ther. 2022 Feb 8;7(1):42. doi: 10.1038/s41392-022-00910-6.

6. Rapid Development of SARS-CoV‑2 Spike Protein Receptor-Binding Domain Self Assembled Nanoparticle Vaccine Candidates. Yin-Feng Kang^#, Cong Sun^#, Zhen Zhuang^#, Run-Yu Yuan^#, Qing-Bing Zheng, Jiang-Ping Li, Ping-Ping Zhou, Xin-Chun Chen, Zhe Liu, Xiao Zhang, Xiao-Hui Yu, Xiang-Wei Kong, Qian-Ying Zhu, Qian Zhong, Miao Xu, Nan-Shan Zhong, Yi-Xin Zeng, Guo-Kai Feng*, Chang-Wen Ke*, Jin-Cun Zhao*, and Mu-Sheng Zeng*.  ACS Nano. 2021 Feb 23;15(2):2738-2752. doi: 10.1021/acsnano.0c08379. Epub 2021 Jan 19.

7. First-in-human pilot study of an integrin α6-targeted radiotracer for SPECT imaging of breast cancer. Shi Gao^#, Bing Jia^#, Guokai Feng^#, Chengyan Dong^#, Hui Du, Lin Bai, Qian Zhong, Qingjie Ma*, Musheng Zeng*, Fan Wang*. Signal Transduct Target Ther. 2020 Aug 11;5(1):147. doi: 10.1038/s41392-020-00266-9.

8. An optimized integrin α6-targeted peptide for positron emission tomography/magnetic resonance imaging of pancreatic cancer and its precancerous lesion. Yan Mei^#, Ying-He Li^#, Xiao-Chun Yang^#, Chao Zhou, Zhi-Jian Li, Xiao-Bin Zheng, Jia-Cong Ye, Cheng Li, Xuan-Hong Zhang, Jian-Min Yuan, Hui-Qiang Huang, Wei Fan, Wei-Guang Zhang*, Mu-Sheng Zeng*, Guo-Kai Feng*. Clin Transl Med. 2020 Aug;10(4):e157. doi: 10.1002/ctm2.157..

9. Integrin α6 targeted positron emission tomography imaging of hepatocellular carcinoma in mouse models. Guo-Kai Feng^#, Jia-Cong Ye^#, Wei-Guang Zhang^#, Yan Mei, Chao Zhou, Yi-Tai Xiao, Xin-Ling Li, Wei Fan*, Fan Wang*, Mu-Sheng Zeng*. J Control Release. 2019 Sep 28:310:11-21. doi: 10.1016/j.jconrel.2019.08.003. Epub 2019 Aug 7.

10. Identification of a sodium pump Na⁺/K⁺ ATPase α1-targeted peptide for PET imaging of breast cancer. Qian Wang^#, Shi-Bing Li^#, Yi-Ying Zhao^#, Da-Nian Dai, Hui Du, Yan-Zhu Lin, Jia-Cong Ye, Jing Zhao, Wei Xiao, Yan Mei, Yi-Tai Xiao, Shi-Chu Liu, Yan Li, Yun-Fei Xia, Er-Wei Song, Gang-Hua Tang, Wei-Guang Zhang, Zhi-Jian Li, Xiao-Bin Zheng, De-Hai Cao, Man-Zhi Li, Qian Zhong, Zhong-Ping Chen, Chao-Nan Qian, Wei Fan*, Guo-Kai Feng*, Mu-Sheng Zeng*. J Control Release. 2018 Jul 10:281:178-188. doi: 10.1016/j.jconrel.2018.05.019. Epub 2018 May 17.

11. SPECT and Near-Infrared Fluorescence Imaging of Breast Cancer with a Neuropilin-1-Targeting Peptide. Guo-Kai Feng^#, Rong-Bin Liu^#, Meng-Qing Zhang^#, Xiao-Xuan Ye, Qian Zhong, Yun-Fei Xia, Man-Zhi Li, Jun Wang, Er-Wei Song, Xing Zhang*, Zhao-Zhong Wu*, Mu-Sheng Zeng*. J Control Release. 2014 Oct 28:192:236-42. doi: 10.1016/j.jconrel.2014.07.039. Epub 2014 Jul 22.

Updated by International Office, Sun Yat-sen University Cancer Center